Longitudinal Analysis of Serum Cytokine Levels and Gut Microbial Abundance Links IL-17/IL-22 With Clostridia and Insulin Sensitivity in Humans - PubMed (original) (raw)
. 2020 Aug;69(8):1833-1842.
doi: 10.2337/db19-0592. Epub 2020 May 4.
Affiliations
- PMID: 32366680
- PMCID: PMC7372073
- DOI: 10.2337/db19-0592
Longitudinal Analysis of Serum Cytokine Levels and Gut Microbial Abundance Links IL-17/IL-22 With Clostridia and Insulin Sensitivity in Humans
Xin Zhou et al. Diabetes. 2020 Aug.
Abstract
Recent studies using mouse models suggest that interaction between the gut microbiome and IL-17/IL-22-producing cells plays a role in the development of metabolic diseases. We investigated this relationship in humans using data from the prediabetes study of the Integrated Human Microbiome Project (iHMP). Specifically, we addressed the hypothesis that early in the onset of metabolic diseases there is a decline in serum levels of IL-17/IL-22, with concomitant changes in the gut microbiome. Clustering iHMP study participants on the basis of longitudinal IL-17/IL-22 profiles identified discrete groups. Individuals distinguished by low levels of IL-17/IL-22 were linked to established markers of metabolic disease, including insulin sensitivity. These individuals also displayed gut microbiome dysbiosis, characterized by decreased diversity, and IL-17/IL-22-related declines in the phylum Firmicutes, class Clostridia, and order Clostridiales This ancillary analysis of the iHMP data therefore supports a link between the gut microbiome, IL-17/IL-22, and the onset of metabolic diseases. This raises the possibility for novel, microbiome-related therapeutic targets that may effectively alleviate metabolic diseases in humans as they do in animal models.
© 2020 by the American Diabetes Association.
Figures
Figure 1
Participants grouped according to IL-17/IL-22 cytokines. A: Gaussian mixture modeling of cytokine mean abundance and variance separates study participants into three discrete groups (columns). Lines within each panel represent repeated measurements of serum cytokine abundance for one individual over the study period. Rows represent serum cytokines (IL-17A, IL-17F, IL-22). CHEX4 is a measurement of background fluorescence intensity and can be treated as a negative control. (Note: different scales on _y_-axis for each row.) B: SSPG (mg/dL) measurement by group. P values for pairwise Wilcoxon test are labeled above the bar plot, and the P value for a one-way ANOVA test is labeled under the bar plot. The analysis in A was based on 297, 371, and 112 repeated measurements for HA, IA, and LA subjects, respectively.
Figure 2
Linear mixed model estimates on fixed effects introduced by LA and HA group. Results for full linear mixed models are shown in
Supplementary Fig. 9
. The comparisons of active vs. inactive groups are presented here. Dashed lines represent the LA group, while regression estimates for the HA group are displayed as horizontal lines. The center of each horizontal line is the β-coefficient of regression, while thick lines represent 50% credible intervals or ±1 SD and thin lines represent 95% credible intervals or ±2 SD. A1C, hemoglobin A1c. This analysis is based on 88 and 229 repeated measurements for HA and LA subjects, respectively.
Figure 3
Differences in the gut microbiome of IL-17/IL-22 LA and HA subjects. A: Shannon diversity estimates for the HA and LA. Mean value of diversity for each participant across the study period is used to generate this plot. The P value from a Wilcoxon test is labeled above the plot. B: _Firmicutes_-to-Bacteroidetes ratio of HA and LA. Mean value of _Firmicutes_-to-Bacteroidetes ratio for each participant across the study period is used to generate this plot. The P value from a Wilcoxon test is labeled above the plot. C: Cladogram representing the LEfSe results for comparing taxa abundance between HA and LA groups. Circles on the cladogram represent the phylogenetic relationship of taxa that are tested, with phylum at the center and operational taxonomic unit (OTU) on the edges. Each point represents a taxonomic unit. Red color covering a dot/region indicates the taxa that are more abundant in the HA group, and blue color covering a dot/area indicates the taxa are more abundant in the LA group.
Figure 4
Bacterial genera whose abundance correlates with serum IL-17. Significant correlations between serum IL-17 and bacterial genus abundance are shown for HA subjects (red panels) and LA subjects (blue panel). Distributions show estimated effect sizes from Bayesian Markov chain Monte Carlo draws after parameter convergence. Panels show bacteria for which the estimated effect is significantly greater or less than zero (95% credible interval does not include zero). This analysis was based on 264 and 100 repeated measurements for HA and LA subjects, respectively.
Similar articles
- IL-17A inhibitors alleviate Psoriasis with concomitant restoration of intestinal/skin microbiota homeostasis and altered microbiota function.
Zhao H, Shang L, Zhang Y, Liang Z, Wang N, Zhang Q, Gao C, Luo J. Zhao H, et al. Front Immunol. 2024 Feb 28;15:1344963. doi: 10.3389/fimmu.2024.1344963. eCollection 2024. Front Immunol. 2024. PMID: 38482003 Free PMC article. - Prebiotic UG1601 mitigates constipation-related events in association with gut microbiota: A randomized placebo-controlled intervention study.
Chu JR, Kang SY, Kim SE, Lee SJ, Lee YC, Sung MK. Chu JR, et al. World J Gastroenterol. 2019 Oct 28;25(40):6129-6144. doi: 10.3748/wjg.v25.i40.6129. World J Gastroenterol. 2019. PMID: 31686768 Free PMC article. Clinical Trial. - Aberrant intestinal microbiota in individuals with prediabetes.
Allin KH, Tremaroli V, Caesar R, Jensen BAH, Damgaard MTF, Bahl MI, Licht TR, Hansen TH, Nielsen T, Dantoft TM, Linneberg A, Jørgensen T, Vestergaard H, Kristiansen K, Franks PW; IMI-DIRECT consortium; Hansen T, Bäckhed F, Pedersen O. Allin KH, et al. Diabetologia. 2018 Apr;61(4):810-820. doi: 10.1007/s00125-018-4550-1. Epub 2018 Jan 29. Diabetologia. 2018. PMID: 29379988 Free PMC article. - [Review of the relation between gut microbiome, metabolic disease and hypertension].
Barna I, Nyúl D, Szentes T, Schwab R. Barna I, et al. Orv Hetil. 2018 Mar;159(9):346-351. doi: 10.1556/650.2018.30787. Orv Hetil. 2018. PMID: 29480046 Review. Hungarian. - Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
Vallianou N, Stratigou T, Christodoulatos GS, Dalamaga M. Vallianou N, et al. Curr Obes Rep. 2019 Sep;8(3):317-332. doi: 10.1007/s13679-019-00352-2. Curr Obes Rep. 2019. PMID: 31175629 Review.
Cited by
- Correlation Between Gut Microbiota Composition and Serum Interleukin 17 (IL-17) in Mice With Type 2 Diabetes and Experimental Periodontitis.
Mo C, Huang M, Yan F, Song M, Fan J, Zhang J. Mo C, et al. Cureus. 2024 Aug 28;16(8):e68005. doi: 10.7759/cureus.68005. eCollection 2024 Aug. Cureus. 2024. PMID: 39211822 Free PMC article. - Effects of immune cells in mediating the relationship between gut microbiota and myelodysplastic syndrome: a bidirectional two-sample, two-step Mendelian randomization study.
Feng Z, Liao M, Guo X, Li L, Zhang L. Feng Z, et al. Discov Oncol. 2024 May 31;15(1):199. doi: 10.1007/s12672-024-01061-6. Discov Oncol. 2024. PMID: 38819469 Free PMC article. - Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease.
Zhou X, Shen X, Johnson JS, Spakowicz DJ, Agnello M, Zhou W, Avina M, Honkala A, Chleilat F, Chen SJ, Cha K, Leopold S, Zhu C, Chen L, Lyu L, Hornburg D, Wu S, Zhang X, Jiang C, Jiang L, Jiang L, Jian R, Brooks AW, Wang M, Contrepois K, Gao P, Rose SMS, Tran TDB, Nguyen H, Celli A, Hong BY, Bautista EJ, Dorsett Y, Kavathas PB, Zhou Y, Sodergren E, Weinstock GM, Snyder MP. Zhou X, et al. Cell Host Microbe. 2024 Apr 10;32(4):506-526.e9. doi: 10.1016/j.chom.2024.02.012. Epub 2024 Mar 12. Cell Host Microbe. 2024. PMID: 38479397 - Dynamic lipidome alterations associated with human health, disease and ageing.
Hornburg D, Wu S, Moqri M, Zhou X, Contrepois K, Bararpour N, Traber GM, Su B, Metwally AA, Avina M, Zhou W, Ubellacker JM, Mishra T, Schüssler-Fiorenza Rose SM, Kavathas PB, Williams KJ, Snyder MP. Hornburg D, et al. Nat Metab. 2023 Sep;5(9):1578-1594. doi: 10.1038/s42255-023-00880-1. Epub 2023 Sep 11. Nat Metab. 2023. PMID: 37697054 Free PMC article. - Dysbiosis of intestinal homeostasis contribute to Whitmania pigra edema disease.
Dai C, Chen X, Qian S, Fan Y, Li L, Yuan J. Dai C, et al. Microb Biotechnol. 2023 Oct;16(10):1940-1956. doi: 10.1111/1751-7915.14308. Epub 2023 Jul 6. Microb Biotechnol. 2023. PMID: 37410351 Free PMC article.
References
- Jiao N, Baker SS, Nugent CA, et al. . Gut microbiome may contribute to insulin resistance and systemic inflammation in obese rodents: a meta-analysis. Physiol Genomics 2018;50:244–254 - PubMed